Nanjing Leads Biolabs Co (HKSE:09887) Total Current Liabilities: HK$554.8 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09887 Nanjing Leads Biolabs Co Ltd HKSE:09887
10 GF Score
Price HK$74.60
! 1 Warning Sign
View Full Analysis

What is Nanjing Leads Biolabs Co Total Current Liabilities?

Nanjing Leads Biolabs Co HKSE:09887 +8.04% 10 Total Current Liabilities is HK$554.8 Mil as of Dec. 2025. GuruFocus rates HKSE:09887 with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Nanjing Leads Biolabs Co's total current liabilities for the quarter that ended in Dec. 2025 was HK$554.8


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


Nanjing Leads Biolabs Co Total Current Liabilities Related Terms


Nanjing Leads Biolabs Co Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Nanjing Leads Biolabs Co's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanjing Leads Biolabs Co Total Current Liabilities Chart

Nanjing Leads Biolabs Co Annual Data
Trend Dec23 Dec24 Dec25
Total Current Liabilities
1,525.29 425.29 554.80

Nanjing Leads Biolabs Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Total Current Liabilities 1,525.29 0.00 425.29 561.31 554.80
HKSE:09887
10GF Score
Nanjing Leads Biolabs Co Ltd HKSE:09887
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanjing Leads Biolabs Co Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Nanjing Leads Biolabs Co's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=39.425+295.137
+Other Current Liabilities+Current Deferred Liabilities
=220.235+0
=554.8

Nanjing Leads Biolabs Co's Total Current Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=39.425+295.137
+Other Current Liabilities+Current Deferred Liabilities
=220.235+0
=554.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of HK$554.8 Mil mean?
Nanjing Leads Biolabs Co (HKSE:09887) has a Total Current Liabilities of HK$554.8 Mil as of Dec. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Nanjing Leads Biolabs Co and its competitors.
Is Nanjing Leads Biolabs Co's Total Current Liabilities too high?
Nanjing Leads Biolabs Co's current Total Current Liabilities is HK$554.8 Mil. Overall, Nanjing Leads Biolabs Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Nanjing Leads Biolabs Co's Total Current Liabilities compare to VRTX and REGN?
Nanjing Leads Biolabs Co's Total Current Liabilities of HK$554.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Nanjing Leads Biolabs Co and its competitors. Nanjing Leads Biolabs Co's current Total Current Liabilities is HK$554.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Leads Biolabs Co stock overvalued right now?
Nanjing Leads Biolabs Co (HKSE:09887) has a current Total Current Liabilities of HK$554.8 Mil. The current Total Current Liabilities is HK$554.8 Mil. Nanjing Leads Biolabs Co's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Nanjing Leads Biolabs Co (HKSE:09887), the current Total Current Liabilities is HK$554.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nanjing Leads Biolabs Co Business Description

Other Exchanges 0DX:Germany
Address Jialingjiang Street, 18E, Floor 8, Building 03, Jiangsu Province, Nanjing, CHN, 210019
Nanjing Leads Biolabs Co Ltd is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Group uses its science-driven R&D approach and three proprietary technology platforms: X-body (4-1BB Engager), LeadsBody (CD3 T Cell Engager), and TOPiKinectics (ADC), for its multi-modal, differentiated pipeline in oncology and autoimmune diseases. It has approximately fourteen drug candidates across oncology and autoimmune diseases. Among these, one core product (LBL-024, a pivotal-stage PD-L1 and 4-1BB dual-targeting bispecific antibody) is being evaluated in several cancer indications and across various Proof-of-Concept (POC) studies. The Group generates maximum revenue from the USA.
10GF Score

Get the complete analysis for HKSE:09887

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$74.60
Price